Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Salmonella</i> in pigs slaughtered in Ecuador: prevalence, serotypes, genotypes and antibiotic resistance.

Veterinary and animal science·2025
Same author

Results of the implementation of a multidisciplinary care protocol for preventing fragility fractures following liver transplantation.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Social cognition impairment associated to a borderline personality disorder subtype linked to attention deficit hyperactivity disorder.

Journal of psychiatric research·2025
Same author

"Vascular tuft sign" in neuroendocrine tumors of the pancreas.

Histology and histopathology·2024
Same author

Mentalizing deficits in borderline personality disorder related to axis I comorbidity: Clinical relevance.

Early intervention in psychiatry·2024
Same author

A Cluster Analysis of Neuropsychological Impairment in Borderline Personality Disorder: Identifying a Neurocognitive Subtype Linked to Attention Deficit Hyperactivity Disorder.

Clinical psychology & psychotherapy·2024
Same journal

Methotrexate and folic acid supplementation in rheumatoid arthritis: A Japanese claims database and 538,985 patients from April 2015 to November 2020.

International journal of clinical pharmacology and therapeutics·2026
Same journal

Cardiac arrest in an adolescent following an overdose of antidepressants comprising sertraline, quetiapine fumarate, and lamotrigine: Case report.

International journal of clinical pharmacology and therapeutics·2026
Same journal

Recombinant human growth hormone in pediatric patients using the FAERS database: Safety profile and update for the period 2004 - 2024.

International journal of clinical pharmacology and therapeutics·2026
Same journal

The triple neuromodulatory-immunomodulatory axis.

International journal of clinical pharmacology and therapeutics·2026
Same journal

Novel intravenous human IVIG in patients with secondary immunodeficiency: Interim analysis of a multicenter, prospective, non-interventional study.

International journal of clinical pharmacology and therapeutics·2026
Same journal

Network meta-analysis of bisphosphonates in the treatment of bone metastases from breast cancer.

International journal of clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Evaluating average bioequivalence using methods for high variability drugs: a case study.

M P Sanchez1, C Gomez, J L Carrasco

  • 1Faculty of Sciences Chemicals and Pharmaceutical Sciences, University of Chile, Santiago, Chile.

International Journal of Clinical Pharmacology and Therapeutics
|October 2, 2008
PubMed
Summary
This summary is machine-generated.

Different statistical methods for assessing average bioequivalence in high variability drugs yield varying conclusions. The choice of bioavailability measures significantly impacts bioequivalence decisions more than the statistical approach itself.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Related Experiment Videos

Last Updated: Jun 29, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Area of Science:

  • Pharmacokinetics and Biopharmaceutics
  • Regulatory Science
  • Statistical Methods in Drug Development

Background:

  • Assessing bioequivalence is crucial for generic drug approval.
  • High variability drugs present unique challenges in bioequivalence evaluation.
  • Existing statistical methods may yield inconsistent conclusions for these drugs.

Purpose of the Study:

  • To compare different statistical approaches for average bioequivalence in high variability drugs.
  • To evaluate the consistency of conclusions across various methods using a single dataset.
  • To discuss the validity and reliability of bioequivalence assessment methods.

Main Methods:

  • Application of diverse average bioequivalence evaluation methods to Furosemide bioavailability data.
  • Inclusion of regulatory recommendations like widening bioequivalence limits.
  • Exploration of scaled limits, scaled statistics, alternative bioavailability measures, and confidence interval construction methods.

Main Results:

  • The choice of bioavailability measures heavily influences bioequivalence decisions.
  • Statistical approaches have a lesser impact on the final bioequivalence conclusion compared to bioavailability measures.
  • The reliability of bioequivalence decisions is primarily dependent on the interpretation of bioavailability measures and drug-specific characteristics.

Conclusions:

  • Bioequivalence assessment for high variability drugs is sensitive to the selected bioavailability measures.
  • Statistical method selection plays a secondary role in determining bioequivalence outcomes.
  • Robust interpretation of bioavailability data and consideration of drug properties are essential for reliable bioequivalence conclusions.